Axel H Schnthal

List of Publications by Year in Descending Order

141 papers	10,013 citations	45 h-index	99 g-index
147 ext. papers	11,054 ext. citations	6.7 avg, IF	6 L-index

#	Paper	IF	Citations
141	Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. *Cancer Gene Therapy*, **2021**, 28, 1058-1070	5.4	4
140	NEO100 enables brain delivery of blood-brain barrier impermeable therapeutics. *Neuro-Oncology*, **2021**, 23, 63-75	1	4
139	Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. *Neuro-Oncology Advances*, **2021**, 3, vdab005	0.9	0
138	Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. *Neuro-Oncology*, **2021**, 23, 1656-1667	1	1
137	Heterogeneous Responses and Isoform Compensation Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer. *Molecular and Cellular Biology*, **2021**, MCB0045921	4.8	0
136	Intravenous delivery of microRNA-133b along with Argonaute-2 enhances spinal cord recovery following cervical contusion in mice. *Spine Journal*, **2020**, 20, 1138-1151	4	4
135	Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. *Neuro-Oncology Advances*, **2020**, 2, vdaa160	0.9	1
134	Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy. *Surgical Neurology International*, **2020**, 11, 389	1	1
133	Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats. *Drug Testing and Analysis*, **2020**, 12, 268-279	3.5	3
132	Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review. *Biochemical Pharmacology*, **2020**, 181, 114149	6	8
131	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. *PLoS ONE*, **2020**, 15, e0238238	3.7	2
130	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas **2020**, 15, e0238238		
129	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas **2020**, 15, e0238238		
128	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas **2020**, 15, e0238238		
127	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas **2020**, 15, e0238238		
126	Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models. *Journal of Neurosurgery*, **2019**, 132, 959-967	3.2	9
125	Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919891567	5.4	4

124	The Rolipram-Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway. *Molecular Cancer Therapeutics*, **2019**, 18, 517-530	6.1	3
123	NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. *Molecular Cancer Therapeutics*, **2018**, 17, 625-637	6.1	16
122	Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model. *Journal of Neurosurgery*, **2018**, 128, 695-700	3.2	22
121	Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	5
120	Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. *Oncology Letters*, **2018**, 15, 1263-1270	2.6	30
119	NEO412: A temozolomide analog with transdermal activity in melanoma and. *Oncotarget*, **2018**, 9, 37026-37041	5.3	12
118	Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	40
117	Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo. *Cancers*, **2018**, 10,	6.6	6
116	Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3-Bromopyruvate Targets beyond Glycolysis. *ACS Chemical Biology*, **2018**, 13, 3054-3058	4.9	13
115	Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts. *CNS Oncology*, **2018**, 7, CNS22	4	25
114	A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells. *Cancer Letters*, **2017**, 400, 161-174	9.9	8
113	Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals. *Archivum Immunologiae Et Therapiae Experimentalis*, **2017**, 65, 285-297	4	17
112	Patient with Recurrent Glioblastoma Responding Favorably to Ketogenic Diet Combined with Intranasal Delivery of Perillyl Alcohol: A Case Report and Literature Review. *Brazilian Neurosurgery*, **2017**, 36, 194-199	0.1	2
111	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
110	A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. *Cancer Letters*, **2016**, 371, 240-50	9.9	18
109	Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas. *Surgical Neurology International*, **2016**, 7, 1	1	16
108	Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	26
107	Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. *Neurosurgical Focus*, **2015**, 38, E12	4.2	113

106	Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. *Neurosurgical Focus*, **2015**, 38, E8	4.2	16
105	Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note. *Journal of Neurosurgery*, **2015**, 123, 362-72	3.2	11
104	Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. *Journal of Biomedical Science*, **2015**, 22, 71	13.3	14
103	A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. *Cancer Letters*, **2015**, 358, 144-151	9.9	14
102	Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. *American Journal of Cancer Research*, **2015**, 5, 1580-93	4.4	35
101	A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. *Molecular Cancer Therapeutics*, **2014**, 13, 1181-93	6.1	35
100	NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. *Molecular Cancer Therapeutics*, **2014**, 13, 2004-17	6.1	38
99	Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. *Neurosurgical Focus*, **2014**, 37, E12	4.2	101
98	Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. *Biochemical Pharmacology*, **2013**, 85, 653-666	6	140
97	Repositioning of Verrucosidin, a purported inhibitor of chaperone protein GRP78, as an inhibitor of mitochondrial electron transport chain complex I. *PLoS ONE*, **2013**, 8, e65695	3.7	19
96	Perillyl alcohol for the treatment of temozolomide-resistant gliomas. *Molecular Cancer Therapeutics* , **2012**, 11, 2462-72	6.1	66
95	Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. *Cancer Letters*, **2012**, 325, 63-71	9.9	47
94	Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. *Cancer Letters*, **2012**, 326, 143-54	9.9	82
93	Targeting endoplasmic reticulum stress for cancer therapy. *Frontiers in Bioscience - Scholar*, **2012**, 4, 412-31	2.4	45
92	Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. *International Journal of Cancer*, **2012**, 130, 2495-504	7.5	12
91	Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. *Scientifica*, **2012**, 2012, 857516	2.6	223
90	Targeting endoplasmic reticulum stress for cancer therapy. *Frontiers in Bioscience - Scholar*, **2012**, S4, 412-431	2.4	55
89	Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. *Cancer Letters*, **2011**, 302, 100-8	9.9	77

88	Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. *Cancer Letters*, **2011**, 304, 33-40	9.9	20
87	Noscapine inhibits tumor growth in TMZ-resistant gliomas. *Cancer Letters*, **2011**, 312, 245-52	9.9	38
86	Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines. *Biochemical Pharmacology*, **2011**, 82, 600-9	6	12
85	Adverse effects of concentrated green tea extracts. *Molecular Nutrition and Food Research*, **2011**, 55, 874-85	5.9	53
84	Preclinical development of novel anti-glioma drugs targeting the endoplasmic reticulum stress response. *Current Pharmaceutical Design*, **2011**, 17, 2428-38	3.3	18
83	Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation. *Journal of Neurosurgery*, **2011**, 114, 689-94	3.2	17
82	Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma **2011**, 291-298		
81	Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. *Molecular Cancer Therapeutics*, **2010**, 9, 631-41	6.1	20
80	Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. *Leukemia Research*, **2010**, 34, 250-3	2.7	21
79	Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2010**, 10, 450-61	2.2	18
78	Glioma-associated endothelial cells are chemoresistant to temozolomide. *Journal of Neuro-Oncology*, **2009**, 95, 13-22	4.8	40
77	Endoplasmic reticulum stress and autophagy as targets for cancer therapy. *Cancer Letters*, **2009**, 275, 163-9	9.9	91
76	Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. *Cancer Letters*, **2009**, 282, 87-97	9.9	42
75	Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. *Blood*, **2009**, 113, 5927-37	2.2	205
74	Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy **2009**, 1037-1056		
73	Celecoxib transiently inhibits cellular protein synthesis. *Biochemical Pharmacology*, **2008**, 75, 395-404	6	29
72	COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. *Molecular Cancer*, **2008**, 7, 38	42.1	53
71	Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. *American Journal of Pathology*, **2008**, 173, 575-85	5.8	77

70	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. *Expert Opinion on Investigational Drugs*, **2008**, 17, 197-208	5.9	64
69	Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. *Cancer Research*, **2008**, 68, 843-51	10.1	111
68	Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. *Molecular Cancer Research*, **2008**, 6, 1268-75	6.6	129
67	Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. *British Journal of Cancer*, **2007**, 97, 1465-8	8.7	89
66	Glioma-associated endothelial cells show evidence of replicative senescence. *Experimental Cell Research*, **2007**, 313, 1192-202	4.2	21
65	Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. *Journal of Biomedical Science*, **2007**, 14, 647-62	13.3	12
64	Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. *Journal of Neurosurgery*, **2007**, 106, 455-62	3.2	78
63	Induction of apoptosis by celecoxib in cell culture: an uncertain role for cyclooxygenase-2. *Cancer Research*, **2007**, 67, 5575-6; author reply 5576	10.1	8
62	HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. *Cancer Research*, **2007**, 67, 10920-8	10.1	116
61	CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non-small-cell lung cancer cells. *Molecular Pharmacology*, **2007**, 72, 1269-79	4.3	40
60	Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. *Molecular Cancer Therapeutics*, **2007**, 6, 1262-75	6.1	110
59	The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. *Cancer Research*, **2007**, 67, 9809-16	10.1	342
58	The intracellular genistein metabolite 5,7,3$4Stetrahydroxyisoflavone mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway. *Free Radical Biology and Medicine* , **2006**, 41, 1225-39	7.8	28
57	EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. *International Journal of Cancer*, **2006**, 119, 1236-48	7.5	57
56	Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. *Neurosurgical Focus*, **2006**, 21, E14	4.2	12
55	Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. *Neurosurgical Focus*, **2006**, 20, E20	4.2	29
54	Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. *Cancer Research*, **2006**, 66, 11115-9	10.1	66
53	Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. *Neurosurgical Focus*, **2006**, 20, E21	4.2	55

52	Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. *Molecular Cancer*, **2006**, 5, 19	42.1	70
51	Potential misidentification of cyclooxygenase-2 by Western blot analysis and prevention through the inclusion of appropriate controls. *Molecular Biotechnology*, **2006**, 34, 329-35	3	13
50	The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. *Journal of Neurosurgery*, **2005**, 103, 526-37	3.2	8
49	Potent mimicry of fibronectin-induced intracellular signaling in glioma cells by the homodimeric snake venom disintegrin contortrostatin. *Neurosurgery*, **2005**, 57, 141-53; discussion 141-53	3.2	14
48	Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. *Cancer Biology and Therapy*, **2005**, 4, 571-82	4.6	71
47	Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. *Blood*, **2005**, 106, 4330-8	2.2	54
46	Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer. *Journal of Thoracic and Cardiovascular Surgery*, **2005**, 130, 1406-12	1.5	24
45	Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-42. *Cancer Research*, **2004**, 64, 2937; author reply 2938	10.1	
44	Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. *Cancer Biology and Therapy*, **2004**, 3, 55-62	4.6	70
43	Inhibition of tumor cell growth by Triton X-100 through specific effects on cell-cycle-regulatory components. *Journal of Biomedical Science*, **2004**, 11, 95-103	13.3	2
42	Measuring cyclin-dependent kinase activity. *Methods in Molecular Biology*, **2004**, 281, 105-24	1.4	7
41	Suppression of the transformed phenotype and induction of differentiation-like characteristics in cultured ovarian tumor cells by chronic treatment with progesterone. *Molecular Carcinogenesis*, **2003**, 38, 160-9	5	6
40	Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis. *Molecular and Cellular Biology*, **2003**, 23, 3043-51	4.8	53
39	Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. *BMC Molecular Biology*, **2002**, 3, 11	4.5	2
38	Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. *Cancer Biology and Therapy*, **2002**, 1, 300-6	4.6	29
37	The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. *Cancer Biology and Therapy*, **2002**, 1, 268-76	4.6	53
36	Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. *Oncogene*, **2001**, 20, 2134-43	9.2	86
35	Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells. *Journal of Biological Chemistry*, **2001**, 276, 47650-7	5.4	64

34	p130/E2F4 binds to and represses the cdc2 promoter in response to p53. *Journal of Biological Chemistry*, **2001**, 276, 1998-2006	5.4	83
33	Role of serine/threonine protein phosphatase 2A in cancer. *Cancer Letters*, **2001**, 170, 1-13	9.9	155
32	Induction of protein phosphatase type 2A in response to disruption of cell-matrix interactions. *Journal of Cellular Physiology*, **2000**, 182, 88-96	7	7
31	Changes in cytoskeletal organization in polyoma middle T antigen-transformed fibroblasts: involvement of protein phosphatase 2A and src tyrosine kinases. *Cytoskeleton*, **2000**, 47, 253-68		4
30	Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor. *Molecular and Cellular Biochemistry*, **2000**, 203, 59-71	4.2	24
29	Redox Regulation of p21, Role of Reactive Oxygen and Nitrogen Species in Cell Cycle Progression **2000**, 311-336		
28	Proliferation of lacrimal gland acinar cells in primary culture. Stimulation by extracellular matrix, EGF, and DHT. *Experimental Eye Research*, **2000**, 70, 639-49	3.7	35
27	Inhibitory phosphorylation of PP1alpha catalytic subunit during the G(1)/S transition. *Journal of Biological Chemistry*, **1999**, 274, 29470-5	5.4	68
26	Mechanisms of G2 arrest in response to overexpression of p53. *Molecular Biology of the Cell*, **1999**, 10, 3607-22	3.5	154
25	Reduction of Ha-ras-induced cellular transformation by elevated expression of protein phosphatase type 2A. *Molecular Carcinogenesis*, **1999**, 24, 246-54	5	16
24	Expression and activity of cell cycle-regulatory proteins in normal and transformed corneal endothelial cells. *Experimental Eye Research*, **1999**, 68, 531-9	3.7	14
23	Role of p53 in aziridinylbenzoquinone-induced p21waf1 expression. *Oncogene*, **1998**, 17, 357-65	9.2	7
22	Anticancer quinones induce pRb-preventable G2/M cell cycle arrest and apoptosis. *Free Radical Biology and Medicine*, **1998**, 24, 848-54	7.8	36
21	Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. *Journal of Biological Chemistry*, **1998**, 273, 5939-47	5.4	106
20	Analyzing gene expression with the use of serine/threonine phosphatase inhibitors. *Methods in Molecular Biology*, **1998**, 93, 35-40	1.4	6
19	Autoregulation of protein phosphatase type 2A expression. *Journal of Biological Chemistry*, **1998**, 273, 19019-24	5.4	110
18	Role of PP2A in intracellular signal transduction pathways. *Frontiers in Bioscience - Landmark*, **1998**, 3, D1262-73	2.8	96
17	Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. *Journal of Biological Chemistry*, **1997**, 272, 29091-8	5.4	66

16	Endoplasmic reticulum stress-inducible protein GRP94 is associated with an Mg2+-dependent serine kinase activity modulated by Ca2+ and GRP78/BiP. *Journal of Cellular Physiology*, **1997**, 170, 115-29	7	19
15	Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells. *Journal of Biological Chemistry*, **1996**, 271, 31915-21	5.4	57
14	Positive regulation of cdc2 gene activity by protein phosphatase type 2A. *Journal of Biological Chemistry*, **1996**, 271, 5988-92	5.4	18
13	Regulation of gene expression by serine/threonine protein phosphatases. *Seminars in Cancer Biology*, **1995**, 6, 239-48	12.7	31
12	Gene amplification and multidrug resistance induced by the phosphatase-inhibitory tumor promoter, okadaic acid. *Carcinogenesis*, **1995**, 16, 637-41	4.6	15
11	Activation of the c-fos promoter by increased internal pH. *Journal of Cellular Biochemistry*, **1995**, 57, 630-40	4.7	6
10	Expression of c-jun proto-oncogene in corneal endothelium. *Experimental Eye Research*, **1994**, 59, 335-41	3.7	5
9	Positive and Negative Regulation of Cell Cycle Progression by Serine/Threonine Protein Phosphatases **1994**, 33-40		1
8	Gene regulation by Ca2+ ATPases. Evidence from the use of thapsigargin, a specific inhibitor of intracellular membrane Ca2+ ATPases. *Annals of the New York Academy of Sciences*, **1992**, 671, 509-11	6.5	2
7	Measuring animal well-being. *Nature*, **1992**, 356, 556	50.4	1
6	Regulation of Proto-Oncogene Expression and Rate of Protein Synthesis by the Tumor Promoter Okadaic Acid **1991**, 337-341		
5	Nuclear protooncogene products: fine-tuned components of signal transduction pathways. *Cellular Signalling*, **1990**, 2, 215-25	4.9	24
4	The Role of FOS in Gene Regulation **1990**, 77-91		1
3	An Update of the Mammalian UV Response: Gene Regulation and Induction of a Protective Function **1989**, 149-165		16
2	Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. *Cell*, **1988**, 54, 325-34	56.2	597
1	Posttranscriptional regulation of c-fos mRNA expression. *Nucleic Acids Research*, **1987**, 15, 1643-59	20.1	213